nach oben

Neurotherapeutics

Erschienen in:

01.10.2017 | Review

Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis

verfasst von: Burhan Z. Chaudhry, Jeffrey A. Cohen, Devon S. Conway

Erschienen in: Neurotherapeutics | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Sphingosine 1-phosphate receptor (S1PR) modulators possess a unique mechanism of action in the treatment of multiple sclerosis (MS). Subtype 1 of the S1PR is expressed on the surface of lymphocytes and is important in regulating egression from lymph nodes. The S1PR modulators indirectly antagonize the receptor’s function leading to sequestration of lymphocytes in the lymph nodes. Fingolimod was the first S1PR modulator to receive regulatory approval for relapsing-remitting MS after 2 phase III trials demonstrated potent efficacy, safety, and tolerability. Fingolimod can cause undesirable effects as a result of its interaction with other S1PR subtypes, which are expressed in diverse tissues, including cardiac myocytes. As such, agents that more selectively target subtype 1 of the S1PR are of interest and are at various stages of development. These include ponesimod (ACT128800), siponimod (BAF312), ozanimod (RPC1063), ceralifimod (ONO-4641), GSK2018682, and MT-1303. Data from phase II trials and early results from phase III studies have been promising and will be presented in this review. Of special interest are results from the EXPAND study of siponimod, which suggest a potential role for S1PR modulators in secondary progressive MS.

Nur mit Berechtigung zugänglich

Radick L, Mehr SR. The latest innovations in the drug pipeline for multiple sclerosis. Am Health Drug Benefits 2015;8;448-53

Gonzalez-Cabrera PJ, Brown S, Studer SM, Rosen H. S1P signaling: new therapies and opportunities. F1000prime Rep 2014;6:109.

Urbano M, Guerrero M, Rosen H, Roberts E. Modulators of the sphingosine 1-phosphate receptor 1. Bioorg Med Chem Lett 2013;23:6377-89.

Aktas O, Kury P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 2010;6:373-82.

Chun J, Hartung HP. Mechanism of action of oral fingolimod [FTY720] in multiple sclerosis. Clin Neuropharmacol 2010;33:91-101.

Zécri FJ. Natural Product to the First Oral Treatment for Multiple Sclerosis: The Discovery of FTY720 (Gilenya)? Curr Opin Chem Biol. 2016;32:60-66

Mao-Draayer Y, Sarazin J, Fox D, et al. The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases. Clin Immunol. 2017;175:10-15

Hunter SF, Bowen JD, Reder AT. The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis. CNS Drugs 2016;30:135-47.

Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 2015;29:565-75.

10.

Kappos L, Antel J, Comi G. et al. Is fingolimod an advancement in the treatment of multiple sclerosis? N Engl J Med 2006;355:1124-40.

11.

Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.

12.

Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis [FREEDOMS II]: a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:545-56.

13.

Cohen JA, Khatri B, Barkhof F, et al. Long-term [up to 4.5 years] treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry 2016;87:468-75.

14.

Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011;10:520-9.

15.

Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis [INFORMS]: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:1075-84.

16.

Ziemssen T, Albrecht H, Haas J, et al. 36 months pangaea: a 5-year non-interventional study of safety, efficacy and pharmacoeconomic data for fingolimod patients in daily clinical practice. Value Health 2015;18:A749.

17.

Gold R, Comi G, Palace J, et al. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol 2014;261:267-76.

18.

Ordonez-Boschetti L, Rey R, Cruz A, et al. Safety and tolerability of fingolimod in Latin American patients with relapsing-remitting multiple sclerosis: the open-label FIRST LATAM study. Adv Ther 2015;32:626-35.

19.

Limmroth V, Haverkamp W, Dechend R, et al. Interim analysis of the START study - extensive electrocardiographic monitoring confirms the good cardiac safety profile of fingolimod. Available at: http://onlinelibrary.ectrims-congress.eu/ectrims/2015/31st/115132/volker.limmroth.interim.analysis.of.the.start.study.-.extensive.html. Accessed August 6, 2017.

20.

Butzkueven H, Weller B, Giacomini PS, et al. Baseline characteristics and interim analysis results of TRANSITION: a 2-year observational study evaluating the safety profile of patients with multiple sclerosis who switched from natalizumab to fingolimod. Available at: http://onlinelibrary.ectrims-congress.eu/ectrims/2015/31st/115617/helmut.butzkueven.baseline.characteristics.and.interim.analysis.results.of.html. Accessed August 6, 2017.

21.

Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA. Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci 2012;323:167-72.

22.

Lindsey JW, Haden-Pinneri K, Memon NB, Buja LM. Sudden unexpected death on fingolomod. Mult Scler 2012;18:1507-8.

23.

Espinosa PS, Berger JR. Delayed fingolomod-associated asystole. Mult Scler 2011;17:1387-9.

24.

Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology 2012;78:672-80

25.

Jeffery DR, Rammohan KW, Hawker K, Fox E. Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis. Expert Rev Neurother 2016;16:31-44.

26.

Pan S, Gray NS, Gao W, et al. Discovery of BAF312 [Siponimod], a potent and selective S1P receptor modulator. ACS Med Chem Lett 2013;4:333-7.

27.

Boudot de la Motte M , Louapre C , Bertrand A, et al. Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse? Mult Scler 2017;23:614-16.

28.

Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol 2012;167:1035-47.

29.

O'Sullivan C, Schubart A, Mir AK, Dev KK. The dual S1PR1/S1PR5 drug BAF312 [Siponimod] attenuates demyelination in organotypic slice cultures. J Neuroinflamm 2016;13:31.

30.

Legangneux E, Gardin A, Johns D. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br J Clin Pharmacol 2013;75:831-41.

31.

Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis [BOLD]: an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013;12:756-67.

32.

Kappos L, Li DK, Stuve O, et al. Safety and efficacy of siponimod [BAF312] in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol 2016;73:1089-98.

33.

Hammond ER. Perspectives on safety and efficacy—the BOLD phase 2 extension study of siponimod in relapsing-remitting multiple sclerosis. JAMA Neurol 2016;73:1052-4.

34.

ClinicalTrials.gov. A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of siponimod [BAF312] in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312. Available at: https://clinicaltrials.gov/ct2/show/NCT01665144?term=NCT01665144&rank=1. Accessed August 6, 2017

35.

Scott FL, Clemons B, Brooks J, et al. Ozanimod [RPC1063] is a potent sphingosine-1-phosphate receptor-1 [S1P1] and receptor-5 [S1P5] agonist with autoimmune disease-modifying activity. Br J Pharmacol 2016;173:1778-92.

36.

Cohen JA, Arnold DL, Comi G, et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis [RADIANCE]: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2016;15(4):373-81.

37.

ClinicalTrials.gov. A phase 2/3, multi-center, randomized, double-blind, placebo-controlled [Part A] and double-blind, double-dummy, active-controlled [Part B], parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple sclerosis patients 2017. Available at https://clinicaltrials.gov/ct2/show/NCT02047734?term=NCT02047734&rank=1. Accessed August 6, 2017.

38.

ClinicalTrials.gov. A phase 3, multi-center, randomized, double-blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple sclerosis patients 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02294058?term=RPC1063&rank=5. Accessed August 6, 2017.

39.

Brossard P, Derendorf H, Xu J, Maatouk H, Halabi A, Dingemanse J. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol 2013;76:888-96.

40.

ClinicalTrials.gov. Multicenter, randomized, double-blind, parallel-group extension to study AC-058B201 to investigate the long-term safety, tolerability, and efficacy of three doses of ponesimod, an oral S1P1 receptor agonist, in patients with relapsing-remitting multiple sclerosis 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT01093326?term=Ponesimod&rank=4. Accessed August 6, 2017.

41.

ClinicalTrials.gov. Multicenter, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02425644. Accessed August 6, 2017.

42.

ClinicalTrials.gov. A safety and efficacy extension study of ONO-4641 [MSC2430913A] in patients with relapsing-remitting multiple sclerosis 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT01226745?term=ONO-4641&rank=1. Accessed August 6, 2017.

43.

Xu J, Gray F, Henderson A, et al. Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers. Clin Pharmacol Drug Dev 2014. doi:10.1002/cpdd.98.

44.

ClinicalTrials.gov. A phase II, multicentre, randomised, double-blind,parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered for a period of 24 weeks in subjects with relapsing-remitting multiple sclerosis 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT01742052?term=MT-1303&rank=5. Accessed August 6, 2017.

45.

Tsai HC, Han MH. Sphingosine-1-phosphate [S1P] and S1P signaling pathway: therapeutic targets in autoimmunity and inflammation. Drugs 2016;76:1067-79.

46.

O'Sullivan S, Dev KK. Sphingosine-1-phosphate receptor therapies: advances in clinical trials for CNS-related diseases. Neuropharmacology 2017;113:597-607.

Titel: Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis
verfasst von: Burhan Z. Chaudhry
Jeffrey A. Cohen
Devon S. Conway
Publikationsdatum: 01.10.2017
Verlag: Springer US
Erschienen in: Neurotherapeutics / Ausgabe 4/2017
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI: https://doi.org/10.1007/s13311-017-0565-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Effectiveness of Daily Prednisolone to Slow Progression of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Multicenter Retrospective Cohort Study

Cladribine to Treat Relapsing Forms of Multiple Sclerosis

Ethical Considerations of Patient-Funded Research for Multiple Sclerosis Therapeutics

Can a Neurosteroid Ameliorate Fragile X-Associated Tremor/Ataxia Syndrome?

Wellness and the Role of Comorbidities in Multiple Sclerosis